PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA 2025
1. PulseSight presented findings on iron dysregulation in AMD at EURETINA Congress. 2. New therapy PST-611 targets iron imbalance, showing potential for AMD treatment. 3. AMD affects 200 million globally, indicating a high unmet medical need. 4. The market for AMD therapies is projected to reach $27.5 billion by 2031. 5. Research highlights ferroptosis as a critical factor in AMD progression.